Lepas by Bayer led a round for anti-allergy drug and food treatment developer Ukko that also featured Continental Grain.

The firm announced its second fund the same day as one of its portfolio companies, University of Wyoming-backed Momentus, successfully listed on Nasdaq.

Harvard-linked Sana Biotechnology will raise as much as $397m if it floats at the upper end and underwriters take up the greenshoe option.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

The autoimmune disease drug developer's series A round has closed at $42.4m after Roche Venture Fund added funding to a first close co-led by AbbVie Ventures.

SR One reinvested in a series B round for the degenerative disorder drug developer that was led by venture fund Logos Capital.

GV and Novartis Venture Fund joined 6 Dimensions Capital in a round that brought Harvard’s oncology drug developer's overall funding to $160m.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The firm, which specialises in commercialising public and corporate research, has closed its largest fund to date.

The mental health benefits platform, which counts Providence Health and Services as an investor, doubled its valuation to $2.3m in the series E round.